Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Vineet Laboratories
|
Samrat Pharmachem
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.53 % | -20.75 % | 18.86 % |
|
5yr average Equity Multiplier
|
-0.87 | 4.27 | 1.83 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 1.52 | 2.61 |
|
5yr Avg Net Profit Margin
|
0.0 | -4.28 % | 3.87 % |
|
Price to Book
|
2.69 | 4.99 | 1.03 |
|
P/E
|
58.9 | 0.0 | 46.22 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 179.8 Days | 58.79 Days |
|
Inventory Days
|
0.0 | 114.74 Days | 28.98 Days |
|
Days Receivable
|
0.0 | 109.14 Days | 80.32 Days |
|
Days Payable
|
0.0 | 115.29 Days | 46.76 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | 1.29 | 16.47 |
|
5yr Avg ROCE
|
21.53 % | -1.66 % | 27.43 % |
|
5yr Avg Operating Profit Margin
|
0.0 | -0.62 % | 5.58 % |
|
5 yr average Debt to Equity
|
-1.45 | 1.24 | 0.21 |
|
5yr CAGR Net Profit
|
43.36 % | n/a | 5.93 % |
|
5yr Average Return on Assets
|
-21.34 % | -2.52 % | 10.3 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 15.89 % | 49.09 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -20.07 % | -0.45 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Vineet Laboratories
|
Samrat Pharmachem
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|